These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 2860134)

  • 1. Short- and long-term studies of bucindolol in mild to moderate hypertension: efficacy, safety, and exercise responses.
    Rosendorff C; Goodman C; Coull A
    J Clin Pharmacol; 1985 Apr; 25(3):233-6. PubMed ID: 2860134
    [No Abstract]   [Full Text] [Related]  

  • 2. A comparison of single doses of bucindolol and oxprenolol in hypertensive patients.
    Webster J; Petrie JC; Robb OJ; Jamieson M; Verschueren J
    Br J Clin Pharmacol; 1985 Oct; 20(4):393-400. PubMed ID: 2866786
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bucindolol, a beta-adrenoceptor blocker with vasodilatory action: its effect in systemic hypertension.
    Rotmensch HH; Rocci ML; Vlasses PH; Swanson BN; Fedder IL; Soyka L; Ferguson RK
    Am J Cardiol; 1984 Aug; 54(3):353-6. PubMed ID: 6147080
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Efficacy and tolerability of tertatolol in the treatment of mild to moderate arterial hypertension. Results of a French multicenter study with 2,338 patients treated over one year].
    Herpin D; Piron J; Bajou B; Lecasble M
    Ann Cardiol Angeiol (Paris); 1989 Oct; 38(8):503-7. PubMed ID: 2574560
    [No Abstract]   [Full Text] [Related]  

  • 5. A comparative study of metoprolol and trichlormethiazide in hypertension.
    Stokkeland OM; Sangvik K; Ditlefsen EM
    Curr Ther Res Clin Exp; 1975 Dec; 18(6):755-68. PubMed ID: 2449
    [No Abstract]   [Full Text] [Related]  

  • 6. Clinical evaluation of bisoprolol in patients with hypertension: interim report.
    Ikeda M; Inagaki Y; Iimura O; Kuramoto K; Takeda T
    J Cardiovasc Pharmacol; 1986; 8 Suppl 11():S139-42. PubMed ID: 2439785
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bucindolol in essential hypertension.
    Reid JL; Curzio J; Vincent J
    Int J Clin Pharmacol Res; 1985; 5(5):293-301. PubMed ID: 2866166
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hemodynamic effects during rest and exercise of bucindolol in hypertensive men.
    Conner DP; Vlasses PH; Clementi RA; Oren A; Deitchman D; Ferguson RK
    J Clin Pharmacol; 1987 Apr; 27(4):300-3. PubMed ID: 2890669
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Methyldopa (Aldomet) in combination with timolol (Blocadren) in the treatment of hypertension.
    Seedat YK
    Curr Ther Res Clin Exp; 1976 Jul; 20(1):10-8. PubMed ID: 8279
    [No Abstract]   [Full Text] [Related]  

  • 10. Dose-effect relationship and long-term effects of bisoprolol in mild to moderate hypertension.
    Weiner L; Frithz G
    J Cardiovasc Pharmacol; 1986; 8 Suppl 11():S106-12. PubMed ID: 2439780
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dose-effect relationship of carvedilol in essential hypertension. An open study.
    Ogihara T; Goto Y; Yoshinaga K; Kumahara Y; Iimura O; Ishii M; Murakami E; Takeda T; Kokubu T; Arakawa K
    Drugs; 1988; 36 Suppl 6():75-81. PubMed ID: 2908305
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long term non-selective and cardioselective beta-receptor blockade in hypertensive patients. Effects on circulatory parameters, catecholamines and renin activity under basal conditions and in connection with exercise and hypoglycemia.
    Hansson BG
    Acta Med Scand Suppl; 1976; 598():1-61. PubMed ID: 13611
    [No Abstract]   [Full Text] [Related]  

  • 13. Timolol maleate (Blocadren) in the treatment of essential hypertension.
    O'Brien KP
    N Z Med J; 1975 Nov; 82(551):293-6. PubMed ID: 1695
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Circadian antihypertensive profile of carvedilol (BM 14190).
    Meyer-Sabellek W; Schulte KL; Distler A; Gotzen R
    J Cardiovasc Pharmacol; 1987; 10 Suppl 11():S119-23. PubMed ID: 2454357
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy of bucindolol in systemic hypertension.
    Kimura S; DeQuattro V; Edmiston WA; Loo R; Thien S; Rigonan K; Deitchman D; Foti A
    Am J Cardiol; 1987 Nov; 60(13):1083-6. PubMed ID: 2890292
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of a new vasodilating beta-blocker, carvedilol, with atenolol in the treatment of mild to moderate essential hypertension.
    Ruilope LM
    Am J Hypertens; 1994 Feb; 7(2):129-36. PubMed ID: 7910028
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy of long-term treatment with nipradilol, a nitroester-containing beta-blocker, in patients with mild-to-moderate essential hypertension.
    Haneda T; Ogawa Y; Akaishi T; Takeda H; Tanazawa S; Inoue H; Ohki Y; Kato J; Morimoto H; Kanaya K
    Clin Ther; 1995; 17(4):667-79. PubMed ID: 8565030
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pafenolol, a new beta 1-selective blocking agent, in mild hypertension. Result of an inpatient study and a subsequent outpatient follow-up.
    Sigurdsson JA; Bengtsson C; Bjurö T
    Eur J Clin Pharmacol; 1984; 26(5):549-53. PubMed ID: 6147255
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-term effects of bisoprolol on blood pressure, serum lipids, and HDL-cholesterol in patients with essential hypertension.
    Frithz G; Weiner L
    J Cardiovasc Pharmacol; 1986; 8 Suppl 11():S134-8. PubMed ID: 2439784
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of arotinolol on serum lipid and apolipoprotein levels in patients with mild essential hypertension.
    Sasaki J; Handa K; Arakawa K
    Clin Ther; 1989; 11(5):580-3. PubMed ID: 2478285
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.